Developer docs
API playgroundTry for free, no card

Search company profiles

Iscador

Full company profile

uuid00212wm

Namestring
Iscador
Legal namestring
Iscador AG
Websiteurl
iscador.com
Company typeenum
Private
Founded yearint
1927
Descriptiontext

Iscador AG is a privately-held Swiss pharmaceutical company (Aktiengesellschaft) headquartered in Arlesheim, Canton Basel-Country, Switzerland, specializing in anthroposophical mistletoe-based preparations for the integrative treatment of cancer. The company's single core product line, ISCADOR®, consists of Viscum album preparations offered in multiple varieties (M, Qu) and strengths (1mg, 2mg, 5mg), with some variants designated "spezifiziert" or "spezial," developed and manufactured at the Institut Hiscia in Arlesheim based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner's anthroposophical medicine philosophy. The company traces its origins to 1927 and claims over 70 years of continuous operation at Institut Hiscia, marking a 100-year milestone in 2024.

The business operates a sales-led, professional-engagement go-to-market model targeting physicians, Heilpraktiker, and other integrative oncology practitioners, supported by a login-protected Professional Portal (Fachkreise), an active event presence (Heilpraktiker-Symposium, Charité Summerschool, Goetheanum Annual Conference, NATUM courses), company tours in Arlesheim, and a public "Leben mit Krebs" knowledge database for patients and relatives. Distribution occurs through Swiss pharmaceutical wholesalers into pharmacies for the home market and through authorized German distribution partners for Germany, with a dedicated shipping facility in Eimeldingen (DE) serving as the European dispatch point under Incoterms FCA Eimeldingen. Pricing is not publicly disclosed as products are prescription medicines routed through regulated pharmacy and partner channels.

Management comprises Sarah Monz and Björn Stehle as authorized representatives (Geschäftsleitung), Alexander Gutmans as Chairman of the Supervisory Board (Verwaltungssrat), Matthias Mütsch as Information Officer, and Kurt Engeloch as finance executive. No parent company, institutional investors, subsidiaries, or revenue figures are disclosed. In May 2026 the company announced the discontinuation of several ISCADOR® variants in Switzerland (spezifiziert 1/2/5 mg) and Germany (spezial 5 mg), available only until mid-2026 while supplies last, indicating a portfolio rationalization alongside continued operation of remaining strengths.

Short descriptiontext

Iscador AG is a privately-held Swiss pharmaceutical company that develops and distributes ISCADOR®, a proprietary line of anthroposophical mistletoe preparations used by physicians and Heilpraktiker for integrative cancer treatment across Switzerland and Germany.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersArlesheim, Switzerland
HQ citystring
Arlesheim
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mistletoe cancer therapy, anthroposophical pharmaceuticals, integrative oncology medicines, herbal cancer preparations, prescription mistletoe extracts
Industry1 code
PRIMARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Anthroposophical Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Preparations Sales
TypeOne Time License
Description

Sale of proprietary mistletoe-based medicinal products (ISCADOR) in various strengths (1mg, 2mg, 5mg) for integrative cancer treatment, distributed through Swiss pharmacies and German distribution partners

iscador.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ISCADOR
Description

Mistletoe-based pharmaceutical preparations for integrative cancer treatment

iscador.com
Core offering1 text field

Iscador AG is a Swiss pharmaceutical company that manufactures and distributes anthroposophical mistletoe-based preparations (ISCADOR®) for the integrative treatment of cancer. Products are derived from Viscum album (mistletoe) and offered in varieties M and Qu at strengths of 1mg, 2mg, and 5mg, developed and produced at the Institut Hiscia based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner. The company's offerings are prescription medicines distributed to medical professionals, pharmacies, and patients seeking holistic supportive cancer care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Iscador AG is a pharmaceutical company offering a single core product line, ISCADOR®, which consists of anthroposophic mistletoe preparations for integrative cancer treatment. The ISCADOR product family includes different varieties (M, Qu) in various strengths (1mg, 2mg, 5mg), with some variants designated as 'spezifiziert' (specified) or 'spezial' (special). The preparations are based on the research of physician Ita Wegman and the ideas of Rudolf Steiner, developed at the Institut Hiscia where they have been manufactured and distributed worldwide for over 70 years.

Product and service1 record
1ISCADOR®
CategoryPrescription Pharmaceutical / Integrative Oncology
Description

Anthroposophic mistletoe (Viscum album) pharmaceutical preparation for integrative cancer treatment. Available in multiple varieties (M, Qu) — some specified as 'spezifiziert' or 'spezial' — and strengths of 1mg, 2mg, and 5mg. Prescribed by physicians and natural health practitioners (Heilpraktiker) for cancer patients seeking supportive oncology care and improved quality of life.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Institut Hiscia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institut Hiscia is the research institution where Iscador AG's mistletoe preparations are developed and manufactured. This represents a core operational partnership for the company's primary products, with over 70 years of collaborative history in anthroposophical medicine research.

iscador.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Leading Swiss-headquartered oncology pharmaceutical major with Basel-area operations; comparable as a mature Swiss specialty pharma operator with extensive oncology relationships, though its portfolio is dominated by targeted biologics rather than botanical preparations.

TypeBroad incumbent
Description

Swiss-headquartered global pharmaceutical major with substantial oncology franchise; provides a broad incumbent comparable on Swiss specialty pharma footprint, regulatory sophistication, and pharmacy channel access that dwarfs Iscador's scale.

TypeDirect peer
Description

Anthroposophical pharmaceutical manufacturer with a broader portfolio of natural medicinal products including oncology-adjacent preparations, operating under the same Rudolf Steiner-based tradition as Iscador.

TypeDirect peer
Description

German pharmaceutical manufacturer of mistletoe preparations for cancer treatment, the most direct competitor to ISCADOR with overlapping oncology claims, prescriber base, and anthroposophical/complementary positioning.

TypeDirect peer
Description

Producer of mistletoe (Viscum album) extracts for integrative oncology, offering comparable prescription-grade preparations that compete for the same prescriber and patient segment as Iscador.

TypeEmerging player
Description

German phytopharmaceutical company producing plant-based prescription medicines for a range of indications; comparable to Iscador in business model (botanical-to-pharma) and DACH market focus, though not in oncology.

TypeDirect peer
Description

Swiss-headquartered anthroposophical medicine company producing natural medicinal and body care products, sharing the anthroposophical heritage and overlapping distribution in pharmacies and specialized practitioners with Iscador.

8Schwabe Pharma AG
TypeRegional player
Description

Swiss producer of plant-based (phytopharmaceutical) medicines with extensive pharmacy distribution in Switzerland; comparable to Iscador as a domestically distributed botanical pharmaceutical peer in the same regulatory and channel environment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iscador

Anthroposophical Pharmaceuticalsiscador.com

Iscador AG is a privately-held Swiss pharmaceutical company that develops and distributes ISCADOR®, a proprietary line of anthroposophical mistletoe preparations used by physicians and Heilpraktiker for integrative cancer treatment across Switzerland and Germany.

What Iscador does

Iscador AG is a privately-held Swiss pharmaceutical company (Aktiengesellschaft) headquartered in Arlesheim, Canton Basel-Country, Switzerland, specializing in anthroposophical mistletoe-based preparations for the integrative treatment of cancer. The company's single core product line, ISCADOR®, consists of Viscum album preparations offered in multiple varieties (M, Qu) and strengths (1mg, 2mg, 5mg), with some variants designated "spezifiziert" or "spezial," developed and manufactured at the Institut Hiscia in Arlesheim based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner's anthroposophical medicine philosophy. The company traces its origins to 1927 and claims over 70 years of continuous operation at Institut Hiscia, marking a 100-year milestone in 2024.

The business operates a sales-led, professional-engagement go-to-market model targeting physicians, Heilpraktiker, and other integrative oncology practitioners, supported by a login-protected Professional Portal (Fachkreise), an active event presence (Heilpraktiker-Symposium, Charité Summerschool, Goetheanum Annual Conference, NATUM courses), company tours in Arlesheim, and a public "Leben mit Krebs" knowledge database for patients and relatives. Distribution occurs through Swiss pharmaceutical wholesalers into pharmacies for the home market and through authorized German distribution partners for Germany, with a dedicated shipping facility in Eimeldingen (DE) serving as the European dispatch point under Incoterms FCA Eimeldingen. Pricing is not publicly disclosed as products are prescription medicines routed through regulated pharmacy and partner channels.

Management comprises Sarah Monz and Björn Stehle as authorized representatives (Geschäftsleitung), Alexander Gutmans as Chairman of the Supervisory Board (Verwaltungssrat), Matthias Mütsch as Information Officer, and Kurt Engeloch as finance executive. No parent company, institutional investors, subsidiaries, or revenue figures are disclosed. In May 2026 the company announced the discontinuation of several ISCADOR® variants in Switzerland (spezifiziert 1/2/5 mg) and Germany (spezial 5 mg), available only until mid-2026 while supplies last, indicating a portfolio rationalization alongside continued operation of remaining strengths.

Iscador firmographics

Firmographics
Name
Iscador
Legal name
Iscador AG
Website
https://iscador.com
Company type
Private
Founded year
1927
Operating status
Operating
Headcount range
11–50 employees
Short description
Iscador AG is a privately-held Swiss pharmaceutical company that develops and distributes ISCADOR®, a proprietary line of anthroposophical mistletoe preparations used by physicians and Heilpraktiker for integrative cancer treatment across Switzerland and Germany.
Ownership category
akta.pro rank

Iscador industry classification

Industry
Product category
Anthroposophical Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology

Keywords

  • Mistletoe cancer therapy
  • Anthroposophical pharmaceuticals
  • Integrative oncology medicines
  • Herbal cancer preparations
  • Prescription mistletoe extracts

Where Iscador is headquartered

Location

Headquarters

HQ city
Arlesheim
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Iscador business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Preparations Sales: Sale of proprietary mistletoe-based medicinal products (ISCADOR) in various strengths (1mg, 2mg, 5mg) for integrative cancer treatment, distributed through Swiss pharmacies and German distribution partners

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Iscador product offering

Product offering

Core offering

Iscador AG is a Swiss pharmaceutical company that manufactures and distributes anthroposophical mistletoe-based preparations (ISCADOR®) for the integrative treatment of cancer. Products are derived from Viscum album (mistletoe) and offered in varieties M and Qu at strengths of 1mg, 2mg, and 5mg, developed and produced at the Institut Hiscia based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner. The company's offerings are prescription medicines distributed to medical professionals, pharmacies, and patients seeking holistic supportive cancer care.

Product overview

Iscador AG is a pharmaceutical company offering a single core product line, ISCADOR®, which consists of anthroposophic mistletoe preparations for integrative cancer treatment. The ISCADOR product family includes different varieties (M, Qu) in various strengths (1mg, 2mg, 5mg), with some variants designated as 'spezifiziert' (specified) or 'spezial' (special). The preparations are based on the research of physician Ita Wegman and the ideas of Rudolf Steiner, developed at the Institut Hiscia where they have been manufactured and distributed worldwide for over 70 years.

Differentiator

Problem solved

Functional benefit

Brands

  • ISCADOR: Mistletoe-based pharmaceutical preparations for integrative cancer treatment

Products and services

  • ISCADOR® Anthroposophic mistletoe (Viscum album) pharmaceutical preparation for integrative cancer treatment. Available in multiple varieties (M, Qu) — some specified as 'spezifiziert' or 'spezial' — and strengths of 1mg, 2mg, and 5mg. Prescribed by physicians and natural health practitioners (Heilpraktiker) for cancer patients seeking supportive oncology care and improved quality of life.

Companies that use Iscador

Customer profile

Segments2 records

Ideal customer profiles2 records

Iscador technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Iscador partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Institut HisciacoreStrategic or Co-development PartnerInstitut Hiscia is the research institution where Iscador AG's mistletoe preparations are developed and manufactured. This represents a core operational partnership for the company's primary products, with over 70 years of collaborative history in anthroposophical medicine research.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Iscador competitors and assessment

Company assessment

Broad incumbents

  • Roche Holding AG: Leading Swiss-headquartered oncology pharmaceutical major with Basel-area operations; comparable as a mature Swiss specialty pharma operator with extensive oncology relationships, though its portfolio is dominated by targeted biologics rather than botanical preparations.
  • Novartis AG: Swiss-headquartered global pharmaceutical major with substantial oncology franchise; provides a broad incumbent comparable on Swiss specialty pharma footprint, regulatory sophistication, and pharmacy channel access that dwarfs Iscador's scale.

Direct peers

  • WALA Heilmittel GmbH: Anthroposophical pharmaceutical manufacturer with a broader portfolio of natural medicinal products including oncology-adjacent preparations, operating under the same Rudolf Steiner-based tradition as Iscador.
  • Helixor Heilmittel GmbH & Co. KG: German pharmaceutical manufacturer of mistletoe preparations for cancer treatment, the most direct competitor to ISCADOR with overlapping oncology claims, prescriber base, and anthroposophical/complementary positioning.
  • Abnoba GmbH: Producer of mistletoe (Viscum album) extracts for integrative oncology, offering comparable prescription-grade preparations that compete for the same prescriber and patient segment as Iscador.
  • Weleda AG: Swiss-headquartered anthroposophical medicine company producing natural medicinal and body care products, sharing the anthroposophical heritage and overlapping distribution in pharmacies and specialized practitioners with Iscador.

Emerging players

  • Bionorica SE: German phytopharmaceutical company producing plant-based prescription medicines for a range of indications; comparable to Iscador in business model (botanical-to-pharma) and DACH market focus, though not in oncology.

Regional players

  • Schwabe Pharma AG: Swiss producer of plant-based (phytopharmaceutical) medicines with extensive pharmacy distribution in Switzerland; comparable to Iscador as a domestically distributed botanical pharmaceutical peer in the same regulatory and channel environment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Iscador social profiles

Digital presence

Iscador financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iscador leadership team

Management profile

Number of profiles

Profiles4 records

Iscador funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iscador M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iscador

What does Iscador do?

Iscador AG is a Swiss pharmaceutical company that manufactures and distributes anthroposophical mistletoe-based preparations (ISCADOR®) for the integrative treatment of cancer. Products are derived from Viscum album (mistletoe) and offered in varieties M and Qu at strengths of 1mg, 2mg, and 5mg, developed and produced at the Institut Hiscia based on the pioneering research of Dr. Ita Wegman and Rudolf Steiner. The company's offerings are prescription medicines distributed to medical professionals, pharmacies, and patients seeking holistic supportive cancer care.

Is Iscador a public or private company?

Iscador is a private company. It is classified as unknown and is currently operating.

When was Iscador founded?

Iscador was founded in 1927. It employs 11 to 50 people.

Where is Iscador based?

Iscador is headquartered in Arlesheim, Switzerland, in the Europe region.

How does Iscador make money?

One revenue line is on record: pharmaceutical Preparations Sales.

Who are Iscador's main competitors?

Broad incumbents on record are Roche Holding AG and Novartis AG. Direct peers are WALA Heilmittel GmbH, Helixor Heilmittel GmbH & Co. KG, Abnoba GmbH and Weleda AG. Bionorica SE is listed as an emerging player. Schwabe Pharma AG is listed as a regional player.

Does Iscador have an API?

No public API is recorded for Iscador.

What industry is Iscador in?

Iscador's product category is Anthroposophical Pharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales